Clinical Trial NU MSK11H01
- Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients with Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
- Principal Investigator
- Jessica Altman
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.NU MSK11H01
- The purpose of this study is to find what effects treatment with two drugs has on the body and leukemia.
- Participants in this study have a blood cancer called acute promyelocytic leukemia (APL). In this disease, immature white blood cells, , build up in the bone marrow.. In this study, tretinoin and arsenic trioxide are being used together. Tretinoin is an approved medicine that causes the leukemia cells in APL to mature. It is related to vitamin A. The second is arsenic trioxide. Arsenic trioxide is an approved medicine for APL that comes back after earlier treatment.
Some of the eligibility criteria include:
- Participant must be at least 18 years of age.
- Participant has been diagnosed with acute promyelocytic leukemia (APL).
- Participant has not had previous treatment for APL, except for tretinoin.
- Description of Treatment
- Treatment is divided into three parts, called induction, consolidation, and maintenance. The goal of first part of treatment, called induction, is to put the leukemia into remission. Participants will receive Tretinoin twice daily by mouth for 35 days. Arsenic trioxide will be given by vein over 1 to 4 hours for a total of 35 doses. The next part of the study is called consolidation. The purpose of consolidation is to keep the leukemia from coming back. Participants will have four consolidation treatments with tretinoin and arsenic trioxide given 2 to 4 weeks apart. Each will consist of tretinoin given twice daily by mouth for 15 days and arsenic trioxide given by vein over 1 to 4 hours for a total of 25 doses. Lastly, because people who have a high number of leukemia cells in their blood at the start of therapy have a higher chance of the leukemia coming back, they will receive maintenance therapy. Participants will be told if they have this risk at the beginning of the study. Participants who fall into this group will begin maintenance therapy. This will consist of Tretinoin by mouth twice daily for 15 days and arsenic trioxide given by vein over 1 to 4 hours for a total of 10 doses. Maintenance therapy will last two years.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jessica Altman
- A Phase I, Multi-Center, Single Arm, Open-Label Study of Mocetinostat (MGCD0103) in Combination with Azacitidine in Subjects with Intermediate or High Risk Myelodysplastic Syndrome (MDS)
- A Phase I, Open, Cohort Dose Escalation Trial with BI 836858 in Patients with Refractory or Relapsed Acute Myeloid Leukemia
- A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
- A Phase 1B Study to Evaluate the Safety and Preliminary Efficacy of Pf-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose ARA-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- A Phase IIa, Multicenter, Open-Label Study Designed to Evaluate the Safety and Efficacy of Escalating Doses of BL-8040 in Adult Subjects with Relapsed/Refractory Acute Myeloid Leukemia
- Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
- A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
- A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse
- A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
- A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients with Leukemias Involving Translocations of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
- Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age = 60 Years)
- A Phase I Study of Metformin and Cytarabine for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia
- A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
last updated: 20-Dec-14 06:13 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.